SAN
DIEGO, June 6, 2023 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that
Dr. Helen Torley, president and
chief executive officer, will present at the Goldman Sachs 44th
Annual Global Healthcare Conference on Tuesday, June 13, 2023, at 8 a.m. PT / 11 a.m.
ET.
A live webcast of the presentation will be available on
the Investor Relations section of the Company's website.
Replays of the webcast will be available for 90 days following the
conference.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company bringing disruptive
solutions to significantly improve patient experiences and outcomes
for emerging and established therapies. As the innovators of the
ENHANZE® technology with the proprietary enzyme
rHuPH20, Halozyme's commercially-validated solution is used to
facilitate the delivery of injected drugs and fluids in order to
reduce the treatment burden to patients. Having touched more than
700,000 patient lives in post-marketing use in five commercialized
products across more than 100 global markets, Halozyme has licensed
its ENHANZE® technology to leading pharmaceutical
and biotechnology companies including Roche, Takeda, Pfizer,
AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon
Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.
Halozyme also develops, manufactures and commercializes, for
itself or with partners, drug-device combination products using its
advanced auto-injector technology that are designed to provide
commercial or functional advantages such as improved convenience
and tolerability, and enhanced patient comfort and adherence. The
Company has a commercial portfolio of proprietary products
including XYOSTED®, TLANDO® and
NOCDURNA® and partnered commercial products and
ongoing product development programs with several pharmaceutical
companies including Teva Pharmaceutical, Pfizer and Idorsia
Pharmaceuticals.
Halozyme is headquartered in San
Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations
facility.
For more information visit www.halozyme.com and
connect with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@antarespharma.com
Dawn Schottlandt
Argot Partners
212-600-1902
Halozyme@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-to-present-at-the-goldman-sachs-44th-annual-global-healthcare-conference-301843265.html
SOURCE Halozyme Therapeutics, Inc.